Breaking Physical Barrier of Fibrotic Breast Cancer for Photodynamic Immunotherapy by Remodeling Tumor Extracellular Matrix and Reprogramming Cancer-Associated Fibroblasts

Investigators developed FPC@S, a photodynamic immunomodulator that targeted the ECM, to improve the photodynamic immunotherapy for fibrotic breast cancer. FPC@S combined a tumor ECM-targeting peptide, a photosensitizer and an antifibrotic drug.